Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Methotrexate added to TAU in early schizophrenia
NCT02074319Phase 1Completed
- Sponsor
- Pakistan Institute of Living and Learning
- Start
- Dec 2013
- Primary completion
- Jul 2015
- Modality
- Orthosteric Ligands
- Countries
- 1
01
Overview
Phase 1, randomised, double-blind trial in schizophrenia, schizoaffective disorder and schizophreniform disorder comparing Methotrexate Arm with Placebo Arm (2 arms). Primary endpoint: Positive and Negative Syndrome Scale at 3 months. Started Dec 2013; status: completed.
02
Drugs
methotrexate
03
Conditions
schizophreniaschizoaffective disorderschizophreniform disorder
Beyond the preview
Go deeper on NCT02074319.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT02074319.